Now available LOQTORZI™

LOQTORZI™ (toripalimab-tpzi) is a programmed death receptor-1 (PD-1)- blocking antibody indicated:

- in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC)

- as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy